Publications

Circulating Cancer Biomarkers

Year of publication 2015


Circulating tumor DNA for triple-negative breast cancer diagnosis and treatment decisions.


**Summary**

Triple-negative breast cancer (TNBC) is a highly aggressive disease characterized by a high number of relapses and poor overall survival. The heterogeneity of the disease and the limited treatment options compared to other breast cancer subtypes mainly explain these clinical outcomes. New biomarkers are urgently needed to improve the management of TNBC. Circulating tumor DNA, identified by tumor-related molecular alterations, could be used in the context of non-invasive “liquid biopsy” and help in TNBC diagnosis and treatment decisions. In this review, we discuss the key issues related to the potential of circulating tumor DNA to improve the management of this disease and the future steps to overcome before its implementation into clinical routine within the next 5 years.

Xavier Pivot, Thomas Suter, Jean Marc Nabholtz, Jean Yves Pierga, Marc Espie, Alain Lortholary, David Khayat, Iris Paupporte, Gilles Romieu, Andrew Kramar, Pierre Fumoleau (2015 Jul 12)

Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study.


**Summary**

This article reports, the cardiac toxicity according to 6- versus 12-month durations of adjuvant trastuzumab in PHARE randomised trial (NCT00381901).

F-C Bidard, C K Y Ng, P Cottu, S Piscuoglio, L Escalup, R A Sakr, F Reyal, P Mariani, R Lim, L Wang, L Norton, V Servois, B Sigal, A Vincent-Salomon, B Weigelt, J-Y Pierga, J S Reis-Filho (2015 May 9)

Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer.


**Summary**

HER3 activating mutations have been shown in preclinical models to be oncogenic and
ligand-independent, but to depend on kinase-active HER2.

Francois-Clement Bidard, Jean-Yves Pierga (2015 Apr 15)
**Clinical utility of circulating tumor cells in metastatic breast cancer.**
*Journal of clinical oncology : official journal of the American Society of Clinical Oncology* : 1622 :
DOI : [10.1200/JCO.2014.57.9714](http://dx.doi.org/10.1200/JCO.2014.57.9714)

**Summary**